In the clinical trials that were conducted, HER2 affibody was labeled using diagnostic radionuclides including fluorine-18 (18F), gallium-68 (68Ga), technetium-99 (99mTc), and 111In to evaluate tumor targeting, biological distribution, blood clearance, dosimetry, and safety (25–28). Here, ERBB2 is linked to neoplasm.